2020台灣生技月 Bio Taiwan 生物科技大展

2020 台灣生技月 南港展覽館

講師

National Taiwan University, SPARK Taiwan

SLC-201 for Amyotrophic Lateral Sclerosis (ALS)

Future Company Type

Others: Licensing and Co-development

Prestartup

Expecting startup year /

No. of team members /3

Stage

Development

Presenter

Name /Hsin-Hsiung Chen

Title /PhD

Email /excitespirit@msn.com

Telephone /(Work) 886-2-23123456 ext. 88378

Fax /886-2-23915293

Mobile /0980959517

About the Team

Our team is led by Professor Show-Li Chen of the Institute of Microbiology, National Taiwan University, and Professor Li-Kai Tsai of the Department of Neurology, National Taiwan University Hospital. He provided advice about the clinical experiment and treatment of ALS disease. The preclinical experiments are mainly carried out by Dr. Hsin-Hsiung Chen of the Institute of Microbiology, National Taiwan University.

The purpose of our team is to develop SLC-201 as a gene therapy drug for Amyotrophic Lateral Sclerosis (ALS) disease. We are looking for the opportunity of product licensing and co-development with pharmaceutical company in the BioAsia Showcase.

Brief Description of main products or services

Amyotrophic lateral sclerosis (ALS) is a neurodegenerative disease with severe muscle atrophy. Riluzole and Edaravone are FDA approved drugs for ALS with limit therapeutic efficacy, testifying to a strong need for new treatment strategies.

The new drug we developed for ALS called SLC-201. SLC-201 is NRIP (nuclear receptor interaction protein) gene carried by Adeno-associated virus to form AAV-NRIP. SLC-201 can express NRIP after entering the cells and NRIP will combine with Acetylcholine receptor (AChR) complex to stabilize neuromuscular junction (NMJ), and further improve motor neurons (MNs) survival, that will achieve the effect of improving motor performance. We performed the multiple muscular injection of SLC-201 in ALS mice (SOD1 mutant mice) to observe the therapeutic effect of SLC-201. In treatment of ALS mice, SLC-201 can improve survival of MNs in spinal cord compared to control group. SLC-201 can improve the innervation and number of NMJ to preserve architecture of NMJ of ALS mice. In the motor behavior, SLC-201 can improve the total distance moved and rearing frequency of ALS mice in the open field test. In the measure of muscle action potential, SLC-201 can improve the CMAP amplitude of ALS mice to reduce nerve degeneration and muscle atrophy of ALS mice.

Contact Person

Name /Hsin-Hsiung Chen

Phone /(Work) 886-2-23123456 ext. 88378

Email /excitespirit@msn.com